Hepatitis C virus infection

New England Journal of Medicine

Volumn 345, Issue 1, 2001, Pages 41-52

  Lauer, Georg M ^a   Walker, Bruce D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; RIBAVIRIN;

ANEMIA; CLINICAL FEATURE; DIAGNOSTIC TEST; DISEASE COURSE; DRUG CONTRAINDICATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TRANSPLANTATION; MONOTHERAPY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RELAPSE; REVIEW; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; BLOOD TRANSFUSION; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; INTERFERON-ALPHA; LIVER; LIVER TRANSPLANTATION; PREVALENCE; RIBAVIRIN;

EID: 0035811625     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200107053450107     Document Type: Review

References (106)

1. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt
2. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
3. The natural history of community-acquired hepatitis C in the United States
4. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients
5. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers: Women and Infants Transmission Study
6. Transmission of hepatitis C virus from mothers to infants
7. Absence of hepatitis C virus transmission but frequent transmission of HIV-1 from sexual contact with doubly-infected individuals
8. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV)
9. Heterosexual transmission of hepatitis C virus and the possible role of coexistent human immunodeficiency virus infection in the index case: A multicentre study of 423 pairings
10. Detection of HCV-RNA in saliva of patients with chronic hepatitis C
11. Experimental transmission of non-A, non-B hepatitis by saliva
12. Hepatitis C virus infection in households of anti-HCV chronic carriers in Italy: A multicentre case-control study
13. Patient-to-patient transmission of hepatitis C virus during colonoscopy
14. Molecular epidemiology of a hepatitis C virus outbreak in a haemodialysis unit: Multicentre Haemodialysis Cohort Study on Viral Hepatitis
15. Transmission of hepatitis C virus by a cardiac surgeon
16. Transmission of hepatitis C virus from a patient to an anesthesiology assistant to five patients
17. The risk of transfusion-transmitted viral infections
18. Testing of individual blood donations for HCV RNA reduces the residual risk of transfusion-transmitted HCV infection
19. Evaluation of automated RNA-extraction technology and a qualitative HCV assay for sensitivity and detection of HCV RNA in pool-screening systems
20. Viral hepatitis in health care personnel at the Johns Hopkins Hospital: The seroprevalence of and risk factors for hepatitis B virus and hepatitis C virus infection
21. Hepatitis C virus infection in medical personnel after needlestick accident
22. Risk of needle-stick injuries in the transmission of hepatitis C virus in hospital personnel
23. Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization
24. Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver
25. Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients
26. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
27. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA
28. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee
29. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line
30. Efficient initiation of HCV RNA replication in cell culture
31. The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site
32. Binding of hepatitis C virus to CD81
33. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3′ nontranslated region are essential for virus replication in vivo
34. Alterations to both the primary and predicted secondary structure of stem-loop IIIc of the hepatitis C virus 1b 5′ untranslated region (5′UTR) lead to mutants severely defective in translation which cannot be complemented in trans by the wild-type 5′UTR sequence
35. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
36. Interferon alfa-2b alone or in combination with ribavirin as initital treatment for chronic hepatitis C
37. Experimental transmission of hepatitis C virus-associated fulminant hepatitis to a chimpanzee
38. Mutation in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
39. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus
40. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa
41. Detection of widespread hepatocyte infection in chronic hepatitis C
42. Analysis of a successful immune response against hepatitis C virus
43. Analysis of successful immune responses in persons infected with hepatitis C virus
44. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C
45. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C
46. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies
47. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus: Identification of multiple epitopes and characterization of patterns of cytokine release
48. Superinfection by homotypic virus in hepatitis C virus carriers: Studies on patients with post-transfusion hepatitis
49. Immunity in chimpanzees chronically infected with hepatitis C virus: Role of minor quasispecies in reinfection
50. Hepatitis C virus-associated fulminant hepatic failure
51. National Institutes of Health Consensus Development Conference Panel statement: Management of hepatitis C
52. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection
53. The long-term pathological evolution of chronic hepatitis C
54. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin
55. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: A 20-year multicenter study
56. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
57. Long-term mortality after transfusion-associated non-A, non-B hepatitis
58. 45-Year follow-up of hepatitis C virus infection in healthy young adults
59. EASL International Consensus Conference on Hepatitis C: Paris, 26-28, February 1999, consensus statement
60. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis
61. Natural history of liver fibrosis progression in patients with chronic hepatitis C
62. Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C
63. Characteristics of patients with dual infection by hepatitis B and C viruses
64. A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis
65. Risk factors for hepatocellular carcinoma among patients with chronic liver disease
66. Hepatocellular carcinoma in Italian patients with cirrhosis
67. Extrahepatic manifestations of HCV infection: Facts and controversies
68. A role for hepatitis C virus infection in type II cryoglobulinemia
69. Mixed cryoglobulinaemia in patients with chronic hepatitis C infection: Prevalence, significance and relationship with different viral genotypes
70. Neurological manifestations of chronic hepatitis C
71. Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders
72. Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma
73. Hepatitis C virus and porphyria cutanea tarda: Evidence of a strong association
74. Lymphocytic sialadenitis of Sjogren's syndrome associated with chronic hepatitis C virus liver disease
75. Clinical and histopathologic analysis of the relationship between lichen planus and chronic hepatitis C
76. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis
77. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C
78. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease
79. The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C
80. Performance of three generations of anti-hepatitis C virus enzyme-linked immunosorbent assays in donors and patients
81. High hepatitis C viraemia and impaired antibody response in patients coinfected with HIV
82. What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?
83. Impact of specimen handling and storage on detection of hepatitis C virus RNA
84. A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C
85. Diagnostic rests for hepatitis C
86. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States
87. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report
88. Recombinant interferon alfa therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial
89. Treatment of chronic hepatitis C with recombinant interferon alfa: A multicenter randomized, controlled trial
90. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon
91. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity
92. Interferon alfa treatment of HCV RNA carriers with persistently normal transaminase levels: A pilot randomized controlled study
93. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy
94. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
95. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis
96. Peginterferon alfa-2a in patients with chronic hepatitis C
97. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
98. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
99. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were nonresponders to a previous treatment
100. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C
101. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus
102. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients
103. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
104. Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C
105. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: A pilot trial of interferon nonresponders
106. A controlled, randomized, multicenter, descending dose phase II trial of pegylated interferon alfa-2A (PEG) vs standard interferon alfa-2a (IFN) for treatment of chronic hepatitis C